Spinal Muscular Atrophy Gene Therapy | ZOLGENSMA | HCP

Natalie, as an infant with SMA, smiling and looking up, framed inside a 3D object in the shape of "1x"

The one-time-only dose to stop SMA progression for patients under 2 years old

ZOLGENSMA is a gene replacement therapy for pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) that is delivered as a single-dose, 1-hour infusion. Baseline tests and post-infusion monitoring for at least 3 months after infusion are required. Administration of a systemic corticosteroid before and after infusion is also required.¹

SEE EFFICACY DATA

Brady, as an infant with SMA, sitting on his mother Nicole’s lap

Novartis Patient Support and provider support

"It was amazing to have [Novartis Patient Support] reach out so quickly because we felt like we had someone in our corner."
— Nicole, Brady’s mom

ACCESS PATIENT SUPPORT

Treating patients 2 years of age or older?

Explore a treatment option

References: 1. ZOLGENSMA. Prescribing information. Novartis Gene Therapies, Inc. 2. Glascock J, Sampson J, Haidet-Phillips A, et al. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. J Neuromuscul Dis. 2018;5(2):145-158.